grant
The LiaFSR system and antimicrobial peptide resistance in enterococci
Organization METHODIST HOSPITAL RESEARCH INSTITUTELocation HOUSTON, UNITED STATESPosted 18 May 2018Deadline 30 Apr 2031
NIHUS FederalResearch GrantFY2026Active ImmunizationActive vaccinationAffectAntibiotic AgentsAntibiotic DrugsAntibiotic ResistanceAntibiotic susceptibilityAntibioticsAntimicrobial ResistanceArchitectureBindingBiochemicalBiologicalCatalytic CoreCatalytic DomainCatalytic RegionCatalytic SiteCatalytic SubunitCell WallCell membraneCenters for Disease ControlCenters for Disease Control and PreventionCenters for Disease Control and Prevention (U.S.)Cessation of lifeClinicalClinical Treatment MoabCo-ImmunoprecipitationsCommon Rat StrainsCritical IllnessCritically IllCytoplasmic MembraneDaptomycinDataDeathDevelopmentDissectionE faecalisE faeciumE. faecalisE. faeciumEarly-Stage Clinical TrialsEndocarditisEngineering / ArchitectureEnterococcusEnterococcus faecalisEnterococcus faeciumEnzyme GeneEnzymesEsteroproteasesExtracellular ProteinGenesGeneticGenetics-MutagenesisGram-Positive BacteriaHospitalsImmune mediated therapyImmunizationImmunochemical ImmunologicImmunologicImmunologicalImmunologicallyImmunologically Directed TherapyImmunologicsImmunotherapyInfectionInfective endocarditisInnate Immune SystemIntegral Membrane ProteinInterphaseIntrinsic Membrane ProteinMDR organismMDR pathogenMass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMediatingMediatorMembraneMiscellaneous AntibioticModelingMolecularMolecular InteractionMonoclonal AntibodiesMorbidityMulti-Drug ResistanceMultidrug ResistanceMultiple Drug ResistanceMultiple Drug ResistantMureinMutagenesisMutagenesis Molecular BiologyN-terminalNH2-terminalOrganismPassive ImmunizationPathway interactionsPatientsPenicillin Binding Protein 4PeptidasesPeptide HydrolasesPeptidesPeptidoglycanPhase 1 Clinical TrialsPhase I Clinical TrialsPhenotypePhosphatidesPhospholipid MetabolismPhospholipidsPlasma MembranePredispositionProtease GeneProteasesProteinasesProteinsProteolytic EnzymesPublic HealthPublishingRatRats MammalsRattusResearchResistanceResistance developmentResistance to Multi-drugResistance to MultidrugResistance to Multiple DrugResistance to antibioticsResistant developmentResistant to Multiple DrugResistant to antibioticsResistant to multi-drugResistant to multidrugRoleS faceiumS faecalisS faeciumS. faceiumS. faecalisS. faeciumSentinelSiteSite-Directed MutagenesisSite-Specific MutagenesisStreptococcus Group DStreptococcus enterococcus groupStreptococcus faceiumStreptococcus faecalisStreptococcus faeciumSurfaceSusceptibilitySystemTargeted DNA ModificationTargeted ModificationTherapeuticTransmembrane ProteinTransmembrane Protein GeneUnited States Centers for Disease ControlUnited States Centers for Disease Control and PreventionVaccinesVancomycin resistant enterococcusVancomycin-resistant enterococciVariantVariationanti-microbialanti-microbial agentanti-microbial druganti-microbial peptideanti-microbial resistantantibiotic drug resistanceantibiotic resistantantimicrobialbasebasesbeta lactam antibioticbeta-Lactamsbiologiccardiolipin synthasecardiolipin synthetasecell envelopeclinical practicecrosslinkdetermine efficacydeveloping resistancedevelopmentaldrug resistant microbesdrug resistant microorganismdrug-resistant microbesefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationevaluate efficacyexamine efficacyextracellularhealth care associated infectionsimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyin vivoliving systemmAbsmembrane structuremonoclonal Absmortalitymouse modelmulti-drug resistantmulti-drug resistant organismmulti-drug resistant pathogenmultidrug resistantmultidrug resistant organismmultidrug resistant pathogenmultiple drug resistant organismmultiple drug resistant pathogenmurine modelnew approachesnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel approachesnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel strategiesnovel strategynovel therapeuticsnovel therapypassive vaccinationpathogenpathwayphase I protocolplasmalemmapreventpreventingprototyperesistance to anti-microbialresistantresistant to antimicrobialresponsesensorsocial rolevaccine antibodiesvaccine induced antibodiesvaccine-induced antibodiesvancomycin resistance enterococcivancomycin resistance in enterococciβ lactam antibioticβ-Lactams
Description preview
Vancomycin-resistant enterococci (VRE) are one of the most challenging organisms in clinical settings.
Indeed, in 2019, enterococci (Enterococcus faecalis and E. faecium) were responsible for approximately 400,000
deaths worldwide, most of them directly attributable to antimicrobial resistance. Further, vancomycin-resistant
Enterococcus faecium…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click